Browsing by Author Kong, Benjamin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2016Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaCarlino, Matteo; Fogarty, Gerald; Guminski, Alexander; Hong, Angela; Kefford, Richard (Rick); Liniker, Elizabeth; Lo, Serigne; Long, Georgina; Menzies, Alexander Maxwel; Ramanujam, Sangeetha; Cooper, Adam; Kong, Benjamin; Wang, T. W.; Western Clinical School: Medicine (Westmead); Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Melonoma & Skin Cancer Res. Inst.; The George Institute for Global Health; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma, OncoImmunology, vol.5, 9, 2016,pp 1-7
2007Allosteric effect of ATP on Na+,K+-ATPase conformational kineticsClarke, Ronald; Kong, Benjamin; Apell, Hans-Jurgen; Chemistry; Central Clinical School: OfficeAllosteric effect of ATP on Na+,K+-ATPase conformational kinetics, Biochemistry, vol.46,(23),2007,pp 7034-7044
2016Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortByth Wilson, Karen; Carlino, Matteo; Carlos, Giuliana R M; Fernandez Penas, Pablo; Hwang, Shelley; Wakade, Deepal; Chou, Shaun; Kefford, Richard F; Kong, Benjamin; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead)Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort, Journal Of The American Academy Of Dermatology, vol.74, 3, 2016,pp 455-461
2002Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytesClarke, Ronald; Hansen, Peter; Kong, Benjamin; Rasmussen, Helge; Buhagiar, Kerrie A; Gray, David F; Chemistry; Northern Clinical School: Medicine; Central Clinical School: Office; Northern Clinical School: MedicineDependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes, American Journal of Physiology: Cell Physiology, vol.283, 5,pp 1511-1521
2004Dietary Cholesterol Alters Na+/K+ Selectivity At Intracellular Na+/K+ Pump Sites In Cardiac MyocytesBuhagiar, Kerrie; Clarke, Ronald; Fernandes, Clyne; Hansen, Peter; Kong, Benjamin; Rasmussen, Helge; Medicine; Chemistry; Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Northern Clinical School: MedicineDietary Cholesterol Alters Na+/K+ Selectivity At Intracellular Na+/K+ Pump Sites In Cardiac Myocytes, American Journal of Physiology: Cell Physiology, vol.286,(2),2004,pp C398-C405
2017Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in MelanomaCarlino, Matteo; Guminski, Alexander; Jakrot, Valerie; Kakavand, Hojabr; Kefford, Richard (Rick); Liniker, Elizabeth; Lo, Serigne; Long, Georgina; Madore, Jason; Menzies, Alexander Maxwel; Saw, Robyn; Scolyer, Richard; Thompson, John; Vilain, Ricardo; Wilmott, James; Cooper, Adam J.; Howle, Julie; Kong, Benjamin; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Westmead Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryDynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma, Clinical Cancer Research, vol.23, 17, 2017,pp 5024-5033
2004Identification Of Potential Regulatory Sites Of The Na+,K+-Atpase By Kinetic AnalysisClarke, Ronald; Kong, Benjamin; Chemistry; Central Clinical School: OfficeIdentification Of Potential Regulatory Sites Of The Na+,K+-Atpase By Kinetic Analysis, Biochemistry, vol.43,(8),2004,pp 2241-2250
2016Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapyCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Long, Georgina; Menzies, Alexander Maxwel; Kefford, Richard F.; Liniker, Elizabeth; Ramanujam, Sangeetha; Saunders, Catherine A B; Western Clinical School: Medicine (Westmead); Medicine Faculty Office; Central Clinical School: Office; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineResidual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy, Pigment Cell & Melanoma Research, vol.29, 5, 2016,pp 572-577
2016Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapyCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Long, Georgina; Menzies, Alexander Maxwel; Kefford, Richard F.; Liniker, Elizabeth; Ramanujam, Sangeetha; Saunders, Catherine A B; Western Clinical School: Medicine (Westmead); Medicine Faculty Office; Central Clinical School: Office; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineResidual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy, Pigment Cell & Melanoma Research, vol.29, 5, 2016,pp 572-577
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210